Emeritus Professor
Institute of Cancer Research, United Kingdom
Prof Ian Judson read Natural Sciences at Cambridge University, majoring in Biochemistry. He subsequently studied Medicine at King’s College Hospital Medical School and trained in Medical Oncology at the Royal Marsden Hospital. He was awarded an MD from Cambridge in 1988 for work on cancer pharmacology and was appointed Senior Lecturer at The Institute of Cancer Research (ICR) in 1989. He was Professor of Cancer Pharmacology at the ICR from 2001 until his retirement in 2016. He remains Emeritus Professor at the ICR. His work initially focused on the development of new anticancer drugs, including temozolomide, abiraterone acetate and everolimus, but expanded into the field of sarcoma in 1991, in which he now has >30 years’ experience. He was involved in the first European clinical trial of imatinib in gastrointestinal stromal tumour (GIST), subsequently being involved in the development of a number of other drugs for this disease. He has been chief investigator for many national and international sarcoma trials and has held the positions of President, Connective Tissue Oncology Society, President, British Sarcoma Group and Chairman, EORTC Soft Tissue and Bone Sarcoma Group (STBSG), for which he was Treasurer until the end of 2020. He was for many years Head of The Royal Marsden Sarcoma Unit and the Sarcoma Clinical Trials team at the ICR.
